+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cytochrome P450 11B2 Mitochondrial - Pipeline Review, H2 2019

  • ID: 4900251
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 42 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Angion Biomedica Corp
  • CinCor Pharma Inc
  • Daiichi Sankyo Co Ltd
  • Damian Pharma AG
  • Merck & Co Inc
  • Recordati SpA
  • MORE
Cytochrome P450 11B2 Mitochondrial - Pipeline Review, H2 2019

Summary

Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Aldosterone synthase is a steroid hydroxylase cytochrome P450 enzyme involved in the biosynthesis of the mineralocorticoid aldosterone. It is only expressed in the zona glomerulosa of the adrenal cortex and is primarily regulated by the renin-angiotensin system. It synthesizes aldosterone in humans and plays an important role in electrolyte balance and blood pressure. Inhibition of aldosterone synthase is used as a medical treatment for hypertension, heart failure, and renal disorders.

Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 5 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Hormonal Disorders, Genito Urinary System And Sex Hormones, Metabolic Disorders, Genetic Disorders and Oncology which include indications Chronic Kidney Disease (Chronic Renal Failure), Congestive Heart Failure (Heart Failure), Hyperaldosteronism, Resistant Hypertension, Cardiometabolic Disease, Cardiovascular Disease, Cushing's Syndrome, Endocrine Gland Disorders, Hypertension, Kidney Fibrosis, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myocardial Fibrosis, Pituitary ACTH Hypersecretion (Cushing Disease), Polycystic Kidney Disease and Primary Hyperaldosteronism.

The latest report Cytochrome P450 11B2 Mitochondrial - Pipeline Review, H2 2019, outlays comprehensive information on the Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5)
  • The report reviews Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Angion Biomedica Corp
  • CinCor Pharma Inc
  • Daiichi Sankyo Co Ltd
  • Damian Pharma AG
  • Merck & Co Inc
  • Recordati SpA
  • MORE
Introduction
Report Coverage
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Overview
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Companies Involved in Therapeutics Development
Angion Biomedica Corp
Boehringer Ingelheim International GmbH
CinCor Pharma Inc
Daiichi Sankyo Co Ltd
Damian Pharma AG
Laekna Therapeutics Shanghai Co Ltd
Merck & Co Inc
Recordati SpA
Selenity Therapeutics Inc
Target Medicals LLC
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Drug Profiles
ANG-3586 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-689648 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CIN-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DP-13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAE-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
osilodrostat phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SE-6440 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CYP11B2 for Cardiovascular Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CYP11B2 for Heart Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CYP11B2 for Chronic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CYP11B2 for Resistant Hypertension - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Dormant Products
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Discontinued Products
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) - Product Development Milestones
Featured News & Press Releases
Nov 15, 2019: CHMP adopts positive opinion for Isturisa
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Angion Biomedica Corp, H2 2019
Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Pipeline by CinCor Pharma Inc, H2 2019
Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Pipeline by Damian Pharma AG, H2 2019
Pipeline by Laekna Therapeutics Shanghai Co Ltd, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Recordati SpA, H2 2019
Pipeline by Selenity Therapeutics Inc, H2 2019
Pipeline by Target Medicals LLC, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019

List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Angion Biomedica Corp
  • Boehringer Ingelheim International GmbH
  • CinCor Pharma Inc
  • Daiichi Sankyo Co Ltd
  • Damian Pharma AG
  • Laekna Therapeutics Shanghai Co Ltd
  • Merck & Co Inc
  • Recordati SpA
  • Selenity Therapeutics Inc
  • Target Medicals LLC
Note: Product cover images may vary from those shown
Adroll
adroll